tetano
Editor, Senior Moderator
Future Microbiol
. 2021 Nov 10.
doi: 10.2217/fmb-2021-0019. Online ahead of print.
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Sarah Aherfi[SUP] 1 2 3 [/SUP], Bruno Pradines[SUP] 2 4 5 6 [/SUP], Christian Devaux[SUP] 2 [/SUP], Stéphane Honore[SUP] 7 8 [/SUP], Philippe Colson[SUP] 1 2 3 [/SUP], Bernard La Scola[SUP] 1 2 3 [/SUP], Didier Raoult[SUP] 1 2 [/SUP]
Affiliations
Abstract
Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with molecular docking data and results from preliminary clinical studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.
Keywords: COVID-19; SARS-CoV-1; SARS-CoV-2; antiviral; coronavirus; drug repurposing; in silico; in vitro testing.
. 2021 Nov 10.
doi: 10.2217/fmb-2021-0019. Online ahead of print.
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Sarah Aherfi[SUP] 1 2 3 [/SUP], Bruno Pradines[SUP] 2 4 5 6 [/SUP], Christian Devaux[SUP] 2 [/SUP], Stéphane Honore[SUP] 7 8 [/SUP], Philippe Colson[SUP] 1 2 3 [/SUP], Bernard La Scola[SUP] 1 2 3 [/SUP], Didier Raoult[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34755538
- DOI: 10.2217/fmb-2021-0019
Abstract
Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with molecular docking data and results from preliminary clinical studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.
Keywords: COVID-19; SARS-CoV-1; SARS-CoV-2; antiviral; coronavirus; drug repurposing; in silico; in vitro testing.